Recruiting

Testing a new cancer medication for tumors with a specific genetic mutation

Plain-English translation of NCT04585750 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing , a new type of cancer medication that works by reactivating a defective gene (TP53 Y220C mutation) found in certain advanced cancers. The medication is being studied in patients whose cancers have continued to grow despite previous treatments. Researchers are first determining the safest dose and how well this treatment works on its own or in combination with another immunotherapy drug.

Many cancers develop a specific mutation in the TP53 gene that helps them grow and resist treatment. This medication targets that exact mutation, offering a potentially new way to help patients whose cancers have stopped responding to standard therapies.

Do you qualify?

You likely qualify if…

you are at least 18 years old (or 12–17 with special approval)
you have been diagnosed with locally advanced or metastatic solid cancer that carries a TP53 Y220C mutation
you have received at least one prior cancer treatment and your cancer is still growing
you are in good enough health to tolerate the medication (ECOG score of 0 or 1)
you have measurable cancer on imaging scans

You likely don't qualify if…

you have received cancer treatment within the past 3 weeks
you have a primary tumor in your brain or a history of cancer spread to the brain (unless stable and not requiring steroids)
you have had a stroke or heart attack within the past 6 months, or have uncontrolled heart conditions
you have active hepatitis B or C, or HIV infection
you cannot take oral medications or have digestive conditions that prevent proper absorption of the drug

What participation looks like

You would take the medication by mouth daily and visit the clinic regularly so doctors can monitor your cancer with scans and blood tests, and check for any side effects. The study has different phases—early phases establish the safest dose, while later phases test how well the medication works. Some patients may receive the medication alone, while others may receive it combined with an immunotherapy drug called given intravenously every three weeks.

AI-generated summary from trial data · Jul 5, 2026 · Not medical advice

Trial locations(77 sites)

United States

University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California

University of San Diego Moores Cancer Center, La Jolla, California

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

Rocky Mountain Cancer Center, Denver, Colorado